QuidelOrtho Corporation

Valuation Analysis

About the Company

QuidelOrtho Corporation en bref

QuidelOrtho Corporation (QDEL) is currently trading at 11,92 € with a market capitalization of 813 M €. The 52-week range spans from 8,65 € to 31,02 €; the current price is 61.6% below the yearly high. Year-over-year revenue growth stands at -10.5%.

💰 Dividende

QuidelOrtho Corporation currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

4 analystes évaluent QuidelOrtho Corporation (QDEL) au consensus : None. L'objectif de cours moyen est de 16,23 €, soit un potentiel de +36.25% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 9,59 € à 33,13 €.

QuidelOrtho Corporation : la thèse d'investissement en détail

QuidelOrtho Corporation (QDEL) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario baissier

Revenue is contracting at -10.5% year-over-year — until that trend reverses, valuation is exposed to further downgrades. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. Short interest sits at 24.1% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Valorisation en contexte

The EV/EBITDA multiple of 7.52x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

À surveiller

• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 36.25% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (24.1%), higher leverage relative to equity.

Trading Data

Related Stocks in the Same Sector

Where can I buy QuidelOrtho Corporation?

Compare top-rated brokers — low fees, trusted providers, fully regulated.